2103 ORAL A randomized, double-blind phase 2 study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC)

✍ Scribed by S. Chan; A. Stopeck; A.A. Joy; S. Verma; A. Lluch; F.K. Liau; S. Kim; P.W. Bycott; D. Soulieres; H. Rugo

• Book ID: 118625707
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 58 KB
• Volume: 5
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(07)70865-0